(19)
(11) EP 2 699 590 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.04.2019 Bulletin 2019/16

(45) Mention of the grant of the patent:
20.02.2019 Bulletin 2019/08

(21) Application number: 12717013.2

(22) Date of filing: 19.04.2012
(51) International Patent Classification (IPC): 
A61K 38/00(2006.01)
(86) International application number:
PCT/US2012/034295
(87) International publication number:
WO 2012/145539 (26.10.2012 Gazette 2012/43)

(54)

ENDOGLIN POLYPEPTIDES AND USES THEREOF

ENDOGLINPOLYPEPTIDE UND IHRE VERWENDUNG

POLYPEPTIDES D'ENDOGLINE ET LEURS UTILISATIONS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 20.04.2011 US 201161477585 P

(43) Date of publication of application:
26.02.2014 Bulletin 2014/09

(60) Divisional application:
19150039.6

(73) Proprietor: Acceleron Pharma Inc.
Cambridge, MA 02139 (US)

(72) Inventors:
  • GRINBERG, Asya
    Lexington, MA 02421 (US)
  • CASTONGUAY, Roselyne
    Malden, MA 02148 (US)
  • WERNER, Eric
    Milton, MA 02186 (US)
  • KUMAR, Ravindra
    Acton, MA 01720 (US)

(74) Representative: EIP 
EIP Europe LLP Fairfax House 15 Fulwood Place
London WC1V 6HU
London WC1V 6HU (GB)


(56) References cited: : 
WO-A1-2007/143023
 WO-A1-2008/151078
   
  • FRANCISCO J. BLANCO ET AL: "Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-[beta] receptor complex", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 204, no. 2, 1 August 2005 (2005-08-01), pages 574-584, XP055030607, ISSN: 0021-9541, DOI: 10.1002/jcp.20311
  • SCHARPFENECKER MARION ET AL: "BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis", JOURNAL OF CELL SCIENCE, vol. 120, no. 6, 1 March 2007 (2007-03-01) , pages 964-972, XP002490785, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB ISSN: 0021-9533, DOI: 10.1242/JCS.002949
  • R. CASTONGUAY ET AL: "Soluble Endoglin Specifically Binds Bone Morphogenetic Proteins 9 and 10 via Its Orphan Domain, Inhibits Blood Vessel Formation, and Suppresses Tumor Growth", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 34, 26 August 2011 (2011-08-26), pages 30034-30046, XP055031457, ISSN: 0021-9258, DOI: 10.1074/jbc.M111.260133
  • ALT AARON ET AL: "Structural and functional insights into endoglin ligand recognition and binding.", PLOS ONE, vol. 7, no. 2, E29948, 8 February 2012 (2012-02-08), pages 1-12, XP002679013, ISSN: 1932-6203
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).